ACS Medicinal Chemistry Letters · 2015 · 51 citations · 28 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationAntibacterial AgentsAntibacterial PharmacologyAntibiotic ResistanceBeta-lactam ResistanceCarbapenem ResistanceEnzyme InhibitionAntibacterial Drug DevelopmentAntibiotic DiscoveryAntimicrobial Drug DevelopmentBeta-lactamase InhibitorsChemical Structure-activity RelationshipsNovel Antibacterial AgentsNovel Antibacterial Drug Discoveryβ-Lactam Antibiotics
A new scaffold, azolylthioacetamide, was constructed and assayed against metallo-β-lactamases (MβLs). The obtained molecules specifically inhibited MβL ImiS, and 1c was found to be the most potent inhibitor, with a K i = 1.2 μM using imipenem as substrate. Structure-activity relationships reveal that the aromatic carboxyl improves inhibitory activity of the inhibitors, but the aliphatic carboxyl does not. Compounds 1c-d and 1h-i showed the best antibacterial activities against E. coli BL21(DE3) cells producing CcrA or ImiS, resulting in 32- and 8-fold reduction in MIC values, respectively; 1c and 1f-j resulted in a reduction in MIC against P. aeruginosa. Docking studies revealed that 1a, 1c, and 1d fit tightly into the substrate binding site of CphA as a proxy for ImiS with the aromatic carboxylate forming interactions with Lys224, the Zn(II) ion, the backbone of Asn233, and hydrophobic portions of the inhibitors aligning with hydrophobic patches of the protein surface.
28
VMD: Visual molecular dynamics
William Humphrey, Andrew Dalke, Klaus Schulten · Journal of Molecular Graphics · 1996 · 66.6K citations
N.O. Concha, Cheryl A. Janson, P. Rowling et al. · Biochemistry · 2000 · 305 citations
Life Sciences, Biology, Chemistry +16